Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
(MedPage Today) -- Up to 90% of patients with advanced small cell lung cancer (SCLC) responded to a PD-L1/VEGF bispecific antibody linked to an antibody-drug conjugate (ADC), a preliminary trial showed. Response rates ranged from 52.4% in patients...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial medpagetoday.com
